Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Jaguar Animal Health, Inc. (JAGX) on August 22, 2016. The report addresses a notice received from the NASDAQ Listing Qualifications Staff regarding the Company's failure to meet continued listing standards.
Key Financial Metrics
- Stockholders' Equity: $1,565,316 (as reported in the Form 10-Q for the period ended June 30, 2016).
- Market Value of Listed Securities: Approximately $14.8 million.
- Net Income: The Company does not meet the net income from continuing operations test.
- Debt and Liquidity: The filing text does not provide specific values for debt or cash flow.
Material Changes and Listing Status
The Company received notification that it no longer complies with NASDAQ Listing Rule 5550(b)(1) due to stockholders' equity falling below the required minimum of $2,500,000. The Company also fails to meet the alternative requirements of a $35 million market value or positive net income from continuing operations. Consequently, the Company has 45 days (until October 6, 2016) to submit a plan to regain compliance.
Outlook, Management Commentary, and Risks
Management intends to submit a compliance plan by the October 6, 2016 deadline. Potential strategies to regain compliance include:
- Strategic partnerships or a potential merger with Napo Pharmaceuticals, Inc., the Company's largest stockholder and former parent.
- Continued sale of common stock under a $15 million Common Stock Purchase Agreement with Aspire Capital Fund, LLC.
Risks and Contingencies: There is no assurance that NASDAQ will accept the compliance plan or that the Company will successfully regain compliance. If the plan is rejected, the Company's stock may be subject to delisting, though an appeal to a NASDAQ hearings panel would be available. The filing includes standard forward-looking statement disclaimers regarding the uncertainty of these plans.
Investor Verification Checklist
- Verify the acceptance status of the Company's compliance plan by the October 6, 2016 deadline.
- Monitor progress on the potential merger or cooperation with Napo Pharmaceuticals, Inc.
- Track the volume and pricing of shares sold under the Aspire Capital Fund Purchase Agreement.
- Review the Company's next Form 10-Q or 10-K for updated stockholders' equity and net income figures.